bortezomib
ダラツムマブdaratumumab(ダラザレックス®)は、日本では2017年9月に承認されたばかりの新薬で、今のところ再発・難治性の多発性骨髄腫に適応があります。 Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaN Engl J Med 2018;3…
Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy. Br J Haematology 2017 PMID: 28169430, DOI: 10.1111/bjh.1453…
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. (Lancet Haematol. 2016, PMID 277517…
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66. www.ncbi.nlm.nih.gov 背景 ダラツムマブはCD38を標的としたヒトIgGκ型モノクローナル抗体であり、直接的、間接的に抗骨髄腫活性を誘導し、濃…
Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma (Br J Haematol 2015;168:55-62) プロテアソーム阻害剤であるボルテゾミブ(BOR)は，細胞の化学療法に対する感受性を増大させ…
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis (Blood 2014;124:2498-2506) CAN2007試験は、再発した原発性ALアミロイドーシスを対象とした、bortezomib週1回または2回投与の第1/2相臨床試験…
Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Pro…
Complete response after autologous stem cell transplant in multiple myeloma. (Cancer Med 2014, PMID 24777883) 著者らは自家幹細胞移植(ASCT)後に完全奏功(CR)を達成した骨髄腫患者の長期予後を評価した。1990年4月から2012年6月までの間に191例がASCT…
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.(Biol Blood Marrow Transplant 2014;20:536-542)標準的BEAMと自家造血…
Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).(Blood 2014;123:1665-1673)rituximab、bortezomib、modified hyper-CVADを組み合わせた寛解導入免疫化学…
